Celldex Therapeutics, Inc. Forecast, price target & analysts
Celldex Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Celldex Therapeutics, Inc. Classifications & Recommendation:
Celldex Therapeutics, Inc. Price Target
| Target Price | $57.25 |
| Price | $20.49 |
| Potential |
179.41%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Celldex Therapeutics, Inc. 2026 .
The average Celldex Therapeutics, Inc. target price is $57.25.
This is
179.41%
register free of charge
$90.00
339.24%
register free of charge
$31.00
51.29%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Celldex Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2026 of
179.41%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.02 | 3.57 |
| 2.03% | 49.09% | |
| EBITDA Margin | -2,733.62% | -6,990.29% |
| 35.28% | 155.72% | |
| Net Margin | -2,316.68% | -6,405.90% |
| 17.77% | 176.51% |
13 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2025 . The average Celldex Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Celldex Therapeutics, Inc. EBITDA forecast 2025. The average Celldex Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Celldex Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.45 | -3.45 |
| 16.10% | 40.82% | |
| P/E | negative | |
| EV/Sales | 194.90 |
13 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Celldex Therapeutics, Inc....
Current Celldex Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 06 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 06 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 20 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
